Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice

HA Jacene, R Filice, W Kasecamp… - Journal of Nuclear …, 2007 - Soc Nuclear Med
We retrospectively evaluated our single-center clinical experience with 90 Y-ibritumomab
tiuxetan and 131 I-tositumomab for therapy of refractory non-Hodgkin's lymphoma (NHL). We …

Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases

…, A Prideaux, Y Du, E Frey, W Kasecamp… - Journal of nuclear …, 2006 - Soc Nuclear Med
The lungs are the most frequent sites of distant metastasis in differentiated thyroid carcinoma.
Radioiodine treatment planning for these patients is usually performed following the Benua…

18F-FDG PET/CT for monitoring the response of lymphoma to radioimmunotherapy

HA Jacene, R Filice, W Kasecamp… - Journal of Nuclear …, 2009 - Soc Nuclear Med
We retrospectively evaluated 18 F-FDG PET/CT for monitoring the response of non-Hodgkin's
lymphoma to radioimmunotherapy. Methods: A total of 33 clinical patients received 131 I-…

[PDF][PDF] A study of age-dependent changes in thyroid function tests in adults

…, EL Nickoloff, TH Hsu, WR Kasecamp… - Journal of Nuclear …, 1979 - Soc Nuclear Med
METHODS Two hundred twenty-five healthy, free-living adults aged 20-80 were studied. None
had a history of thyroid disease, goiter, or medications known to alter thyroid function. No …

Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning—patient studies

…, G Sgouros, Y Du, H Jacene, WR Kasecamp… - Medical …, 2009 - Wiley Online Library
The estimation of organ residence time is essential for high‐dose myeloablative regimens in
radioimmunotherapy (RIT). Frequently, this estimation is based on a series of simple planar …

Initial experience with tositumomab and I-131-labeled tositumomab for treatment of relapsed/refractory Hodgkin lymphoma

…, S Piantadosi, D Serena, W Kasecamp… - Molecular imaging and …, 2017 - Springer
Purpose To determine the maximum tolerated dose (MTD) of [ 131 I]tositumomab in patients
with refractory/recurrent Hodgkin lymphoma (HL) and to preliminarily determine if [ 131 I]…

[HTML][HTML] Prospective SPECT-CT organ dosimetry-driven radiation-absorbed dose escalation using the in-111 (111in)/yttrium 90 (90y) ibritumomab tiuxetan (Zevalin®) …

…, JA Bianco, RJ Hammes, M Jung, W Kasecamp… - Cancers, 2021 - mdpi.com
Simple Summary We prospectively evaluated the feasibility of SPECT-CT/planar organ
dosimetry-based radiation dose escalation radioimmunotherapy in patients with recurrent non-…

[PDF][PDF] Tc-99m human serum albumin: a suitable agent for plasma volume measurements in man

…, HH Mikesell, U Scheffel, W Kasecamp… - Journal of Nuclear …, 1978 - Soc Nuclear Med
MATERIALS AND METHODS Seven patients with documented alcoholic liver disease and
portal hypertension, and nine patients fol lowing coronary artery bypass surgery were studied*…

Bowel visualization during indium-111-labelled diethylene triamine penta-acetic acid cisternography due to massive cerebrospinal fluid leak: Case report and review …

PJ Jeffery, S Sostre, LR Scherer, W Kasecamp… - European journal of …, 1990 - Springer
We report a case of massive cerebrospinal fluid (CSF) leakage where the tracer injected
intra-thecally for radionuclide cisternography was later visualized in the bowel as well as the …

Right ventricular ejection fraction measured by first-pass intravenous krypton-81m: reproducibility and comparison with technetium-99m

…, PA Tibbits, T Beck, D Koller, W Kasecamp… - The American journal of …, 1985 - Elsevier
Study of the effects of various diseases and therapeutic manipulation of pulmonary vascular
resistance on the right ventricle has been restricted by methodologic limitations. The …